Background: Sodium-glucose co-transporter 2 (SGLT2) inhibitors, empagliflozin, dapagliflozin and ertugliflozin are part of modern therapy of T2DM. A wide range of these agents enhances glycemic control but has further cardiovascular and renal advantages that are crucial in modern T2DM management. Objectives : This research will therefore seek to comparing empagliflozin, dapagliflozin and ertugliflozin in the context of T2DM with regard to HbA1c and FPG management, alongside safety profiles. Study design: A retrospective cohort study. Place and duration of study. Department of endocronolgy hmc Peshawar from jan 2021 to jan 2022 Methods :Demographic and clinical factors of 300 T2DM patients treated with empagliflozin, dapagliflozin or ertugliflozin were analyzed in a retrospective study. Random blood glucose levels were recorded over the initial period of 6 months along with HbA1c, FPG and data on adverse events as well. Quantitative data analysis concerned with mean changes, standard deviations and p-values as a measure of differences between groups. Results : The mean decrease in HbA1c was 0. 85% ± 0. 12% in the empagliflozin group and 0. 83 % ± 0. 13% with dapagliflozin, 0. 81% ± 0. 14% with ertugliflozin p = 0. 28 FPG reductions were similar across the groups: 20. 3 ± 4. 2 for empagliflozin, 19. 8 ± 4. 5 for dapagliflozin and 19. 5 ± 4. 7 for ertugliflozin (p = 0. 33). The total of adverse effects reported also showed no difference between the groups (p = 0. 42).